Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
Czechia
University Hospital Ostrava, Ostrava Switzerland
University Hospital Zurich, Zurich, Canton of Zurich